Background: Several clinical studies have evaluated the role of COPD in patients with communityacquired pneumonia (CAP). We investigated the systemic inflammatory response of patients with CAP (CAP + COPD) and patients without associated COPD (CAP only). Methods: Clinical, microbiologic, and immunologic data were collected from 367 prospective patients on admission to hospital during a 3-year period. Comparative analyses were performed between patients with CAP + COPD (n = 117) and those with CAP only (n + 250) and between patients with and without domiciliary use of inhaled corticosteroids (ICSs) and oral corticosteroids. Results: Detailed characteristics of clinical severity and prognosis (mortality on hospitalization and at 30 and 90 days) were similar between the CAP + COPD and CAP-only groups. The readmission rate and the frequency of previous pneumonia were higher in the group of patients with CAP + COPD. On day 1 (admission to hospital), patients with CAP + COPD had significantly lower serum levels of tumor necrosis factor-α, IL-1, and IL-6 compared with the CAP-only group; levels of the remaining inflammatory biomarkers (C-reactive protein, procalcitonin, IL-8, and IL-10) were similar at days 1 and 3. The exclusion of patients with domiciliary use of ICS and oral corticosteroids confirmed lower levels of TNF-α on day 1 in patients with CAP + COPD. Finally, lower levels of IL-6 were found only among those patients with COPD who were currently using ICS. Conclusions: Our prospective study demonstrates a different, disease-specific, early inflammatory pattern between patients with CAP with and without associated COPD. These findings are not completely corticosteroid mediated. © 2013 American College of Chest Physicians.

Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD

CRISAFULLI, Ernesto;
2013-01-01

Abstract

Background: Several clinical studies have evaluated the role of COPD in patients with communityacquired pneumonia (CAP). We investigated the systemic inflammatory response of patients with CAP (CAP + COPD) and patients without associated COPD (CAP only). Methods: Clinical, microbiologic, and immunologic data were collected from 367 prospective patients on admission to hospital during a 3-year period. Comparative analyses were performed between patients with CAP + COPD (n = 117) and those with CAP only (n + 250) and between patients with and without domiciliary use of inhaled corticosteroids (ICSs) and oral corticosteroids. Results: Detailed characteristics of clinical severity and prognosis (mortality on hospitalization and at 30 and 90 days) were similar between the CAP + COPD and CAP-only groups. The readmission rate and the frequency of previous pneumonia were higher in the group of patients with CAP + COPD. On day 1 (admission to hospital), patients with CAP + COPD had significantly lower serum levels of tumor necrosis factor-α, IL-1, and IL-6 compared with the CAP-only group; levels of the remaining inflammatory biomarkers (C-reactive protein, procalcitonin, IL-8, and IL-10) were similar at days 1 and 3. The exclusion of patients with domiciliary use of ICS and oral corticosteroids confirmed lower levels of TNF-α on day 1 in patients with CAP + COPD. Finally, lower levels of IL-6 were found only among those patients with COPD who were currently using ICS. Conclusions: Our prospective study demonstrates a different, disease-specific, early inflammatory pattern between patients with CAP with and without associated COPD. These findings are not completely corticosteroid mediated. © 2013 American College of Chest Physicians.
2013
Administration
Inhalation
Administration
Oral
Adrenal Cortex Hormones
Aged
Aged
80 and over
C-Reactive Protein
Community-Acquired Infections
Comorbidity
Female
Humans
Inflammation
Interleukin-1
Interleukin-6
Male
Middle Aged
Pneumonia
Prognosis
Prospective Studies
Pulmonary Disease
Chronic Obstructive
Retrospective Studies
Severity of Illness Index
Tumor Necrosis Factor-alpha
Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1030118
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 43
social impact